Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serelaxin in Acute Heart Failure (RELAX-AHF-2)
NCT01870778Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Primary completion
- Jan 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 35
01
Overview
A Phase 3 trial of serelaxin in Acute Heart Failure (AHF), sponsored by Novartis. Started Oct 2013; status: completed.
02
Drugs
serelaxin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT01870778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01870778.